<DOC>
	<DOCNO>NCT00771134</DOCNO>
	<brief_summary>This study evaluate efficacy safety Lu AA39959 treatment depression patient bipolar disorder .</brief_summary>
	<brief_title>Efficacy Safety Lu AA39959 Patients With Bipolar Depression</brief_title>
	<detailed_description>Bipolar disorder common lifelong psychiatric disorder characterize recurrent mood swing manic hypomanic episode alternate depressive episode long duration . Patients spend time depression ( hypo ) mania life time . The main goal treatment bipolar disorder resolution symptom , return premorbid level social function prevention future episode . Although many treatment bipolar disorder , approve , limitation use due safety tolerability issue . Recommendations exist use mood stabiliser , antipsychotic combination thereof without antidepressant polypharmacy employ many case reason concern . There major medical need effective treatment monotherapy reduce potential adverse effect . This study evaluate efficacy safety new drug , Lu AA39959 , treatment depression patient bipolar disorder .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patients suffer major depressive episode bipolar II I disorder , accord DSMIV TR Current major depressive episode bipolar II I disorder , accord DSMIV TR Moderate severe depression History least one document mania hypomania episode Absence current mania hypomania Any current psychiatric disorder bipolar disorder define DSMIV TR Any substance disorder previous 6 month Use psychoactive medication ( include mood stabilizer ) within 2 week randomisation study ECT within 6 month study Female childbearing potential use adequate contraception Other protocoldefined inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Depression</keyword>
	<keyword>Bipolar I Disorder</keyword>
	<keyword>Bipolar II Disorder</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Randomised control</keyword>
	<keyword>Multicenter</keyword>
	<keyword>Clinical study</keyword>
	<keyword>Mania</keyword>
</DOC>